Over $1 billion in federal funding got slashed for this polluting industry. The clean cement industry might be facing the end of the road, before it ever really got rolling.

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at the ...

The new drug was approved by the UK medicines regulator on 14th February and is a successor to Sobi's long-established haemophilia A therapy Eloctate (efmoroctocog alfa), also sold by partner ...

Novo Nordisk to present phase 3 trials across hemophilia portfolio, reinforcing commitment to research in rare blood disorders, at ISTH 2025 Novo Nordisk to present phase 3 trials across ...

The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting drug it has developed to create a new standard of patient care for ...